Evidence map›Paper›PMID 41889052›Full record

ArticleJACC. Advances2026

Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study.

Moa P Lee, Sarah H Koenigsberg, Mohammad Y Anwar, Laura M Raffield, Zhaotong Lin, Anna F Ballou, John N Booth, Thibaut Davy-Mendez, Helina Kassahun, Shia T Kent and 7 more

Abstract read
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Moa P LeeDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Sarah H KoenigsbergDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Mohammad Y AnwarDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Laura M RaffieldDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
Zhaotong LinDepartment of Statistics, Florida State University, Tallahassee, Florida, USA.
Anna F BallouDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
John N BoothCenter for Observational Research, Amgen Inc, Thousand Oaks, California, USA.
Thibaut Davy-MendezDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA; Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Helina KassahunGlobal Development, Amgen Inc, Thousand Oaks, California, USA.
Shia T KentCenter for Observational Research, Amgen Inc, Thousand Oaks, California, USA.
J Antonio G LópezGlobal Development, Amgen Inc, Thousand Oaks, California, USA.
Keri L MondaCenter for Observational Research, Amgen Inc, Thousand Oaks, California, USA.
Kari E NorthDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Rina YaroshDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Misa GraffDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Christy L AveryDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA; Carolina Population Center, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: Christy_avery@unc.edu.

Funding

Characterizing pleiotropy in cardiometabolic phenotypes among diverse populations - Admin SupplR01HL142825 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AVERY, CHRISTY LEIGH · 2019 to 2023
$3.3M
Phenotypic consequences of lipoprotein(a) in diverse populationsR01HL172887 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christy Leigh Avery, Mariaelisa Graff · 2025 to 2026
$2.9M
Addressing Barriers to the Comprehensive Use of Statins in HIV: The ABACUS-HIV StudyK01HL169020 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Thibaut Davy-Mendez · 2023 to 2026
$600k
A Phenome-Wide Association Study to Identify and Characterize Phenotypic Effects of Lp(a)F32HL149256 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, MOA PARK · 2020 to 2022
$121k
Triangulating causal effects of sleep, inflammation, and cardiometabolic diseaseF31HL177899 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sarah H. Koenigsberg · 2025 to 2026
$84k
NHLBI NIH HHS F31 HL177899NHLBI NIH HHS F32 HL149256NHLBI NIH HHS K01 HL169020NHLBI NIH HHS R01 HL142825NHLBI NIH HHS R01 HL172887
6 · The paper itself

Abstract

backgroundMendelian randomization studies suggest a causal effect of lipoprotein(a) (Lp(a)) on atherosclerotic cardiovascular disease. Noncardiovascular effects (eg, diabetes risk) are inadequately investigated.

objectivesIn this noninterventional phenome-wide association study designed to better understand the potential causal role of Lp(a), direct causal phenotypic effects of exposure to Lp(a) were estimated. Also, the association between LPA null allele rs41272114 with type 2 diabetes was assessed, and ancestry-specific Lp(a) thresholds were determined.

methodsIn the UK Biobank (n = 425,677 adults, 55% female), we studied 1,456 phenotypes spanning 18 classes using 4 ancestry-specific polygenic risk scores and false discovery rate multiple testing correction. Network deconvolution Mendelian randomization was leveraged to separate direct from indirect (ie, associations via mediating variables) causal phenotypic effects and account for confounding, reverse causation, and bidirectionality.

resultsLp(a) was significantly associated with 80 phenotypes across 7 classes. Higher Lp(a) exposure had significant direct causal effects, independent of low-density lipoprotein cholesterol, on coronary artery disease (OR: 1.36; 95% CI: 1.21-1.54) and glycated hemoglobin (HbA1c; β = 0.099; 95% CI: 0.051-0.15) only. Very low Lp(a) exposure was not associated with type 2 diabetes (OR: 0.92; 95% CI: 0.64-1.31) or HbA1c (β = -0.016; 95% CI: -0.062 to 0.030). Among European and African ancestries, 86 (77th percentile) and 93 (59th percentile) nmol/L optimally discriminated myocardial infarction risk, respectively.

conclusionsIncreasing Lp(a) exposure had direct, independent causal effects on coronary artery disease and HbA1c only; very low Lp(a) exposure is suggested to not be causally associated with type 2 diabetes. The optimal European and African ancestry threshold to stratify cardiovascular risk is comparable, and below 125/105 nmol/L in current U.S./European medical professional society guidelines.

Indexed as

atherosclerotic cardiovascular diseaselipoprotein(a)Mendelian randomizationphenome-wide association studytype 2 diabetes

Identifiers

PMID41889052
PMCPMC13050038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.